- Trials with a EudraCT protocol (6,716)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
6,716 result(s) found for: Multicenter Study.
Displaying page 225 of 336.
EudraCT Number: 2020-000405-83 | Sponsor Protocol Number: VP-VYV-683-3201 | Start Date*: 2021-04-09 | |||||||||||
Sponsor Name:Vanda Pharmaceuticals Inc. | |||||||||||||
Full Title: A multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of iloperidone for 4 weeks in the treatment of patients with acute manic episodes associated wi... | |||||||||||||
Medical condition: Acute manic episodes associated with Bipolar I Disorder | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Completed) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-003193-48 | Sponsor Protocol Number: Darvadstrocel-3004 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Takeda Development Center Americas, Inc. | |||||||||||||
Full Title: A Phase 3, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of Darvadstrocel in the Treatment of Complex Perianal Fistula in Pediatric Subjects with Crohn’s Disease over a Period o... | |||||||||||||
Medical condition: Complex Perianal Fistulas in Crohn’s Disease | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: PL (Trial now transitioned) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002893-11 | Sponsor Protocol Number: PASIPHAE | Start Date*: 2017-08-14 |
Sponsor Name:Karolinska University Hospital | ||
Full Title: A phase 2, international, multicenter, open-labeled, randomized trial of PAlbociclib and fulvestrant vs. Standard oral capecitabine In Patients with Hormone receptor positive/HER2 negative Advanced... | ||
Medical condition: Hormone receptor positive/HER2 negative advanced breast cancer with endocrine resistance | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: SE (Prematurely Ended) GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2018-000221-31 | Sponsor Protocol Number: DS8201-A-U301 | Start Date*: 2019-02-06 | |||||||||||
Sponsor Name:Daiichi Sankyo Inc. | |||||||||||||
Full Title: A Phase 3, multicenter, randomized, open-label, active-controlled study of trastuzumab deruxtecan (DS-8201a), an anti-HER2-antibody drug conjugate, versus treatment of investigator’s choice for HER... | |||||||||||||
Medical condition: Unresectable/metastatic breast cancer with human epidermal growth factor receptor 2 (HER2)-positive expression | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) CZ (Completed) FR (Completed) GR (Completed) DE (Completed) IT (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-002041-31 | Sponsor Protocol Number: I4X-MC-JFDA | Start Date*: 2016-09-19 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Single-Arm, Multicenter, Phase 2 Study of Gemcitabine-Carboplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Patients with Locally Advanced or Metastatic Squamous Non-Small Cell... | |||||||||||||
Medical condition: Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2013-000490-79 | Sponsor Protocol Number: AB12006 | Start Date*: 2015-09-18 | |||||||||||
Sponsor Name:AB Science | |||||||||||||
Full Title: A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5... | |||||||||||||
Medical condition: Metastatic colorectal cancer after 1 previous line of treatment | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Prematurely Ended) ES (Completed) CZ (Completed) SK (Prematurely Ended) HU (Completed) GB (Prematurely Ended) FR (Completed) CY (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002742-68 | Sponsor Protocol Number: C3601002 | Start Date*: 2018-04-24 |
Sponsor Name:Pfizer Inc. | ||
Full Title: A Phase 3 Prospective, Randomized, Multicenter, Open-Label, Central Assessor-Blinded, Parallel Group, Comparative Study to Determine the Efficacy, Safety and Tolerability of Aztreonam-Avibactam (AT... | ||
Medical condition: Complicated intra-abdominal infection (cIAI) and hospital-acquired pneumonia/ventilator-associated pneumonia (HAP/VAP) | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: HU (Completed) CZ (Completed) ES (Ongoing) BG (Completed) GR (Completed) HR (Completed) IT (Completed) RO (Ongoing) | ||
Trial results: View results |
EudraCT Number: 2020-004501-30 | Sponsor Protocol Number: V181-003 | Start Date*: 2022-06-14 | |||||||||||
Sponsor Name:Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A Phase 2, Randomized, Double-Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Three Different Potency Levels of V181 (Dengue Quadrivalent Vaccine rDENVΔ30 [live, attenuated]) ... | |||||||||||||
Medical condition: Prevention of dengue disease in toddlers, children, and adults in endemic areas, as well as travelers to endemic areas | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FI (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003733-40 | Sponsor Protocol Number: CA183-002 | Start Date*: 2007-03-30 | |||||||||||
Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||
Full Title: A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gem... | |||||||||||||
Medical condition: Locally advanced or metastatic Transitional Cell Carcinoma (TCC) of the urothelium | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) BE (Completed) ES (Completed) DK (Prematurely Ended) IT (Prematurely Ended) GR (Completed) GB (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-002133-37 | Sponsor Protocol Number: ARGX-113-1705 | Start Date*: 2019-06-06 | |||||||||||||||||||||
Sponsor Name:argenx BVBA | |||||||||||||||||||||||
Full Title: A Long-Term, Single-Arm, Open-Label, Multicenter, Phase 3 Follow-on Trial of ARGX-113-1704 to Evaluate the Safety and Tolerability of ARGX-113 in Patients with Myasthenia Gravis having Generalized... | |||||||||||||||||||||||
Medical condition: Myasthenia Gravis | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: NL (Completed) CZ (Completed) DE (Completed) DK (Completed) BE (Completed) HU (Completed) IT (Completed) | |||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2022-003365-38 | Sponsor Protocol Number: VTX958-202 | Start Date*: 2023-03-31 | |||||||||||
Sponsor Name:Ventyx Biosciences, Inc. | |||||||||||||
Full Title: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of VTX958 in Participants with Moderately to Severely Active Crohn’s D... | |||||||||||||
Medical condition: Moderately to severely active Crohn’s disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SK (Prematurely Ended) LT (Completed) DE (Prematurely Ended) HU (Prematurely Ended) IT (Completed) PL (Prematurely Ended) BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-001483-38 | Sponsor Protocol Number: BAY1163877/19131 | Start Date*: 2019-09-02 | |||||||||||
Sponsor Name:Bayer AG | |||||||||||||
Full Title: An international, multicenter, Phase 1b/2 study of rogaratinib (BAY 1163877) in combination with atezolizumab as first-line treatment in cisplatin-ineligible patients with FGFR-positive locally adv... | |||||||||||||
Medical condition: FGFR-positive locally advanced or metastatic urothelial carcinoma | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) FR (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-003012-36 | Sponsor Protocol Number: ALX0061-C202 | Start Date*: 2015-03-23 | |||||||||||
Sponsor Name:Ablynx NV | |||||||||||||
Full Title: A Phase IIb Multicenter, Randomized, Double-blind Study of ALX-0061 Administered Subcutaneously as Monotherapy, in Subjects with Moderate to Severe Rheumatoid Arthritis who are Intolerant to Methot... | |||||||||||||
Medical condition: Rheumatoid Arthritis (RA) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) HU (Completed) CZ (Completed) ES (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004779-39 | Sponsor Protocol Number: NH19708 | Start Date*: 2018-02-26 | ||||||||||||||||
Sponsor Name:Roche Farma S.A(Soc unipersonal)que realiza el ensayo en España y que actua como representante F.Hoffmann-La Roche LTD. | ||||||||||||||||||
Full Title: AN OPEN-LABEL, SINGLE-ARM, MULTICENTER STUDY TO ASCERTAIN THE OPTIMAL STARTING DOSE OF MIRCERA® GIVEN SUBCUTANEOUSLY FOR THE MAINTENANCE TREATMENT OF ANEMIA IN PEDIATRIC PATIENTS WITH CHRONIC KIDNE... | ||||||||||||||||||
Medical condition: Chronic renal anemia | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||
Trial protocol: ES (Completed) LT (Completed) HU (Completed) FR (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-000638-20 | Sponsor Protocol Number: M19-130 | Start Date*: 2020-01-22 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of Elsubrutinib and Upadacitinib Given Alone or in Combination (ABBV-599 Combination) in Subjects with Moderately to Severely Active Systemic ... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) HU (Completed) NL (Completed) BG (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000019-27 | Sponsor Protocol Number: 0431-049 | Start Date*: 2007-03-14 | |||||||||||
Sponsor Name:Merck & Co., Inc | |||||||||||||
Full Title: A Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of Sitagliptin Compared With Metformin in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control | |||||||||||||
Medical condition: type II diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Completed) FI (Completed) IE (Completed) HU (Completed) DK (Completed) ES (Completed) GB (Completed) AT (Completed) GR (Completed) DE (Completed) EE (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-000325-21 | Sponsor Protocol Number: A6181122 | Start Date*: 2007-05-02 | |||||||||||
Sponsor Name:Pfizer Inc. - 235 East 42nd Street - New York - 10017 | |||||||||||||
Full Title: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 3 STUDY OF SUNITINIB IN METASTATIC COLORECTAL CANCER PATIENTS RECEIVING IRINOTECAN, 5-FLUOROURACIL AND LEUCOVORIN (FOLFIRI) AS FIRST LINE TREATMENT | |||||||||||||
Medical condition: first-line treatment of patients with metastatic colorectal cancer. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) IE (Completed) DE (Completed) AT (Completed) ES (Completed) HU (Completed) BE (Completed) PT (Completed) CZ (Completed) GB (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-004280-27 | Sponsor Protocol Number: GS-US-576-6220 | Start Date*: 2022-03-28 | |||||||||||
Sponsor Name:Gilead Sciences, Inc. | |||||||||||||
Full Title: An Open-label, Multicenter, Phase 2 Study of Sacituzumab Govitecan Combinations in First-line Treatment of Patients with Advanced or Metastatic Non−Small-Cell Lung Cancer (NSCLC) Without Actionable... | |||||||||||||
Medical condition: Non-small-cell lung cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) IT (Trial now transitioned) DE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2008-003003-31 | Sponsor Protocol Number: EORTC 26082 – 22081 | Start Date*: 2009-12-01 | |||||||||||
Sponsor Name:EORTC Headquarters | |||||||||||||
Full Title: Radiation therapy and concurrent plus adjuvant Temsirolimus (CCI-779) versus chemo-irradiation with Temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter – a ra... | |||||||||||||
Medical condition: patients with newly diagnosed glioblastoma (GBM) without methylation of the DNA-repair enzyme O6-methylguanin-DNA-methyltransferase (MGMT) gene promoter | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) FR (Completed) NL (Completed) BE (Completed) GB (Completed) AT (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-000146-35 | Sponsor Protocol Number: EFC12347 | Start Date*: 2012-10-12 | |||||||||||
Sponsor Name:sanofi-aventis recherche & développement | |||||||||||||
Full Title: 6-Month, Multicenter, Randomized, Open-label, Parallel-group Study Comparing the Efficacy and Safety of a New Formulation of Insulin Glargine and Lantus® in Insulin-Naïve Patients with Type 2 Diabe... | |||||||||||||
Medical condition: Type 2 diabetes mellitus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) SE (Completed) FI (Completed) EE (Completed) CZ (Completed) LV (Completed) LT (Completed) NL (Completed) BG (Completed) SK (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
